BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 26086566)

  • 61. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
    Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
    Dochez V; Caillon H; Vaucel E; Dimet J; Winer N; Ducarme G
    J Ovarian Res; 2019 Mar; 12(1):28. PubMed ID: 30917847
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
    Moore RG; Jabre-Raughley M; Brown AK; Robison KM; Miller MC; Allard WJ; Kurman RJ; Bast RC; Skates SJ
    Am J Obstet Gynecol; 2010 Sep; 203(3):228.e1-6. PubMed ID: 20471625
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.
    Bast RC; Skates S; Lokshin A; Moore RG
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S5-8. PubMed ID: 22543921
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HE4 in the differential diagnosis of ovarian masses.
    Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
    Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.
    Li PL; Zhang X; Li TF; Wang LL; Du LT; Yang YM; Li J; Wang HY; Zhang Y; Wang CX
    Clin Chim Acta; 2015 Jan; 439():148-53. PubMed ID: 25445414
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [HE4 a biomarker of ovarian cancer].
    Presl J; Kučera R; Topolčan O; Novotný Z; Vrzalová J; Fuchsova R; Betincová L; Rokyta Z
    Ceska Gynekol; 2012 Oct; 77(5):445-9. PubMed ID: 23116350
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Validation of the Cut-points Recommended for ROMA Using the Roche Elecsys CA125 and HE4 Assays.
    Cradic KW; Lasho MA; Algeciras-Schimnich A
    Ann Clin Lab Sci; 2018 Jan; 48(1):90-93. PubMed ID: 29531002
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.
    Michalak M; Gąsiorowska E; Markwitz EN
    Ginekol Pol; 2015 Apr; 86(4):256-61. PubMed ID: 26117983
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
    Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
    J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
    Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
    Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
    Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
    Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
    Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
    Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings.
    Wilailak S; Chan KK; Chen CA; Nam JH; Ochiai K; Aw TC; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Charakorn C; Sumpaico WW
    J Gynecol Oncol; 2015 Jan; 26(1):46-53. PubMed ID: 25310857
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.